Fact-checked by Grok 2 weeks ago

Acepromazine

Acepromazine, chemically known as 10-[3-(dimethylamino)propyl]phenothiazin-2-yl methyl ketone maleate, is a synthetic derivative that functions as a potent tranquilizer and in . Originally developed in the 1950s as an agent for human treatment, it has been repurposed exclusively for animal use due to its efficacy in sedation and the availability of superior alternatives for human psychiatric care. Approved by the FDA for dogs, cats, and horses, acepromazine is commonly administered via injection or oral routes to achieve rapid calming effects, typically lasting 4–6 hours, without providing analgesia. The drug's primary mechanism of action involves antagonism of central dopaminergic receptors, particularly D2 subtypes, which inhibits signaling in the to produce tranquilization and reduce anxiety. It also blocks alpha-1 adrenergic receptors, leading to and , while exhibiting additional antihistaminic, , and antiserotonergic properties that contribute to its and muscle-relaxant effects. In veterinary practice, acepromazine is most frequently employed as a pre-anesthetic to facilitate handling and , to alleviate during travel, and to manage acute behavioral issues such as or in clinical settings. Specialized applications include adjunctive therapy for in horses, where it helps reduce pain-induced stress, though dosages must be carefully titrated to avoid cardiovascular compromise. Despite its widespread use since the mid-20th century, acepromazine carries notable risks, including profound that can exacerbate or , impairing coordination, and rare paradoxical excitation manifesting as increased , particularly in certain breeds. Contraindications include animals with cardiovascular instability. Although older literature suggested risks, recent studies have not confirmed increased activity in animals with seizure disorders, though caution is still advised. Genetic mutations such as the ABCB1 deletion in collies and related breeds can heighten and toxicity risk; testing or dose reduction is recommended in at-risk breeds. In , it may induce penile , necessitating avoidance in stallions, while overdose can lead to respiratory depression and rapid cardiovascular collapse, though recovery is typically swift with supportive care. Overall, its role remains foundational in veterinary protocols, balanced by vigilant monitoring to mitigate adverse effects.

Chemical properties

Molecular structure

Acepromazine is a phenothiazine derivative characterized by the molecular formula C₁₉H₂₂N₂OS for its free base form, with a molecular weight of 326.46 g/mol. Its IUPAC name is 1-[10-[3-(dimethylamino)propyl]phenothiazin-2-yl]ethanone. The core structure consists of a tricyclic phenothiazine ring system, featuring two benzene rings connected by a central heterocyclic ring containing sulfur and nitrogen heteroatoms. At position 2 on one benzene ring, an acetyl group (-COCH₃) is attached, while at the nitrogen (position 10), a 3-(dimethylamino)propyl side chain (-CH₂CH₂CH₂N(CH₃)₂) is substituted. This configuration can be textually represented as a phenothiazine scaffold with the acetyl substitution enhancing its lipophilicity compared to unsubstituted analogs. In comparison to , another aliphatic , acepromazine features an at position 2 instead of a chloro , which contributes to its pronounced sedative profile with lower potency and reduced extrapyramidal side effects relative to chlorpromazine's more antipsychotic-oriented activity. Both share the same 3-(dimethylamino)propyl side chain at N10, classifying them within the low-potency, high-sedation aliphatic subclass of .

Physical and pharmacological characteristics

Acepromazine maleate is a to pale yellow crystalline powder, often described as odorless or nearly so. It is typically administered in as the maleate salt form to enhance and stability. The compound exhibits good in , exceeding 10 mg/mL, and is also soluble in , facilitating its formulation in various vehicles. Its value is approximately 9.3 for the side chain at 25°C, influencing its ionization and behavior in physiological environments. Acepromazine maleate is sensitive to and air, with solutions prone to under such exposure; it should be stored in a tightly sealed, light-resistant container at in a cool, dry place to maintain potency. Common dosage forms include injectable solutions at concentrations of 1-10 mg/mL for intramuscular or intravenous use, and oral tablets in 10 mg or 25 mg strengths; may involve preparing custom oral suspensions or gels for veterinary applications, always protecting from . Pharmacologically, acepromazine is classified as a low-potency neuroleptic, characterized by prominent effects through and antiemetic properties via blockade. The core contributes to its moderate , aiding tissue distribution.

Pharmacology

Mechanism of action

Acepromazine primarily exerts its sedative effects through antagonism of D2 receptors in the (CNS), which inhibits and leads to reduced spontaneous activity, muscular relaxation, and antipsychotic-like tranquility. This blockade occurs postsynaptically, particularly at D2 subtypes, contributing to the drug's overall calming influence without direct properties. Secondary pharmacological actions include antagonism, which promotes peripheral and can result in , an effect that is particularly prominent in veterinary species such as and compared to its limited use in human medicine. also antagonizes histamine H1 receptors and muscarinic receptors, further enhancing through antihistaminic and mechanisms, respectively. Unlike or agents, acepromazine lacks significant activity at receptors or GABA_A channels, relying instead on its receptor blockade profile for . The properties of acepromazine stem from its antagonism at the in the , suppressing emetic signals without affecting gastrointestinal motility directly. These effects are dose-dependent: low doses produce mild calming with minimal , while higher doses induce profound and more noticeable cardiovascular changes.

Pharmacokinetics

Acepromazine is rapidly absorbed following intramuscular () or intravenous () administration in veterinary species, with peak plasma concentrations typically achieved within 5-20 minutes after IV dosing and slightly longer for IM routes. Oral is also rapid, following kinetics in a two-compartment model, but is variable and route-dependent; in , oral bioavailability ranges from approximately 20% at higher doses (1.3-1.5 mg/kg) to 55% at lower doses (0.5 mg/kg), attributed to dose-dependent saturation of pre-systemic . In horses, oral and results in detectable plasma levels up to 72 hours, though absolute bioavailability values are not well-established and generally lower than parenteral routes. Data on oral bioavailability in cats remain limited, with erratic absorption reported that may vary between individuals. The drug exhibits a high (Vd) of approximately 6.6 L/kg in horses due to its , facilitating extensive tissue penetration including easy crossing of the blood-brain barrier to exert effects. Protein binding is extensive, exceeding 99% in equine , which contributes to its prolonged presence in tissues despite relatively short plasma half-lives. Similar distribution patterns are observed in and , with high promoting widespread and potential for accumulation in lipophilic tissues. Acepromazine undergoes hepatic metabolism, producing major inactive metabolites such as 2-(1-hydroxyethyl) and 2-(1-hydroxyethyl)promazine . These metabolites result from oxidation processes, with additional evidence of metabolism by red blood cells in . While specific involvement has not been definitively characterized in veterinary , the drug's hepatic clearance aligns with derivatives processed via oxidative pathways. occurs primarily via the kidneys as metabolites, with acepromazine and its derivatives detectable in for up to 48 hours post- administration in and potentially longer in other . elimination varies by , route, and study: in dogs, reported as 2.5 hours (oral) to 7.1 hours () or 15.9 hours (oral at higher doses); ~3 hours in (oral); and 2.5–8.6 hours in (shorter for ~2.5–5.2 hours, longer for oral ~6–8.6 hours). and clearance vary by , route, and study, with potential for prolonged effects via oral routes or in young animals due to immature hepatic function, increasing accumulation risk with repeated dosing.

Veterinary applications

In dogs and cats

Acepromazine is commonly used in and as a and tranquilizer to facilitate handling of fractious or anxious animals during veterinary examinations, treatments, grooming, and diagnostic procedures such as . It is frequently employed as a pre-anesthetic agent to reduce anxiety, promote muscle relaxation, and ease the induction of general . The drug is also administered orally or by injection to manage and during car travel, and to calm pets during stressful events like thunderstorms or . In behavioral management, it helps control acute or responses in clinical settings, though it provides no effects.

In horses

In horses, acepromazine is utilized to tranquilize fractious animals, aiding in routine procedures such as shoeing, transportation, and veterinary examinations. It serves as a pre-anesthetic sedative to facilitate smoother anesthesia induction and has been associated with reduced perioperative mortality risks. Low doses are applied to support lameness evaluations by mildly relaxing the animal without causing significant ataxia, improving gait observation. Additionally, it is used as adjunctive therapy for laminitis to alleviate stress and digital vasospasm, often in combination with other treatments, and with local anesthetics for minor surgical interventions.

In other species

Acepromazine is employed for sedation in exotic pets, including rabbits and , as well as for immobilization of and restraint of and . In rabbits, it facilitates handling and minor procedures, while in , it aids in calming for examinations or transport. For , such as zoo animals, it supports capture and restraint protocols, and in livestock like , it helps control during veterinary interventions. The sedative effects are consistent across mammals, providing neuroleptic tranquility without analgesia. Typical dosing varies by species: rabbits receive 0.5-2 mg/kg intramuscularly (IM), birds 0.1-1 mg/kg IM, and cattle 0.05-0.1 mg/kg intravenously (IV), with adjustments based on individual response and procedure requirements. For swine, doses of 0.1-0.2 mg/kg IM are used for restraint. Administration is primarily via IM or IV routes for reliable onset, as oral delivery exhibits variable absorption and is infrequently utilized. In food-producing animals like cattle and swine, withdrawal periods are essential to avoid residues; for instance, a 7-day meat withdrawal is recommended for swine. Acepromazine is frequently combined with to enhance in and settings, providing deeper and muscle relaxation for capture of like large mammals. However, its can vary significantly across , often requiring adjunct agents for adequate restraint, and it is not approved for routine use in food-producing animals in certain regions due to residue concerns and lack of established safety data.

Adverse effects

In dogs and cats

Acepromazine administration in dogs and cats commonly leads to , which is the most significant and is dose-dependent, resulting from blockade that causes . This can be exacerbated by rapid intravenous injection, potentially leading to cardiovascular collapse, and is particularly concerning in animals with pre-existing or shock. may also occur, often in combination with other like opioids, due to suppression of sympathetic tone. Respiratory depression is another common effect, manifesting as reduced respiratory rate associated with the drug's sedative properties. In , acepromazine can cause discoloration to pinkish, reddish-brown, or brownish-red hues due to metabolites, which is harmless and resolves spontaneously. is a potential , especially during general , arising from alpha-1 receptor blockade that impairs . Recent studies indicate that acepromazine does not lower the seizure threshold and is generally safe for use in animals with a history of seizures, though individual monitoring is advised. Dogs may experience paradoxical excitation or as an idiosyncratic reaction, characterized by increased , restlessness, or behavior instead of , affecting a small of individuals. Prolonged recovery from is also reported, particularly in dogs homozygous for the ABCB1-1Δ (MDR1) mutation, common in breeds such as Collies and Shepherds, where deficiency allows higher brain concentrations of the drug, intensifying and extending . for the MDR1 mutation is recommended prior to administration in at-risk breeds to mitigate risks. Monitoring of is essential during acepromazine use in both and to detect and manage promptly. The drug should be avoided or used with extreme caution in dehydrated animals or those with cardiovascular compromise, as it can worsen and .

In horses

In horses, acepromazine administration commonly induces , manifesting as uncoordinated movement, and at higher doses may lead to recumbency due to excessive . A notable adverse effect unique to male horses is penile prolapse, resulting from relaxation or of the retractor penis muscle due to alpha-adrenergic blockade; this can persist and become irreversible in some cases, particularly with repeated or high doses. Cardiovascular effects include severe from peripheral , which is exacerbated in hypovolemic, dehydrated, or endotoxemic and may precipitate collapse or cardiovascular instability. Sedation duration typically lasts 2–4 hours but can be prolonged up to 8 hours or more in horses with compromised hepatic function, as acepromazine undergoes extensive liver metabolism. Acepromazine should be used with caution in neonatal foals (under 10 days of age) due to immature hepatic metabolism and increased cardiovascular sensitivity, which may prolong drug effects and heighten adverse reaction risks. Foals older than 1 month can generally be managed similarly to adults. To mitigate risks, the lowest effective dose should be employed, with intravenous administration performed slowly to minimize hypotension; co-administration with alpha-2 agonists such as xylazine or detomidine can counteract vasodilatory effects and stabilize hemodynamics.

Special considerations

Acepromazine is contraindicated in animals with known to phenothiazines. It should also be avoided in patients with severe cardiac disease or , given its alpha-adrenergic blocking effects that can lead to profound . Drug interactions with acepromazine are significant and require careful management. It potentiates the effects of depressants, such as barbiturates and opioids, leading to enhanced and respiratory depression, necessitating dose reductions when co-administered. Concurrent use with other alpha-blockers can intensify , while phenothiazines like acepromazine may increase the of organophosphates, making inadvisable in animals exposed to such compounds. Overdose of acepromazine typically manifests as profound , , respiratory compromise, and potentially , with effects persisting longer than at therapeutic doses. There is no specific available; treatment is supportive and includes intravenous fluid administration to maintain and perfusion, along with vasopressors such as to counteract . Close monitoring of in a veterinary intensive care setting is essential to manage complications. Several precautions apply to the use of acepromazine across species. It provides no analgesic effects and should not be relied upon for pain management, requiring concurrent administration of appropriate analgesics when needed. Special monitoring is advised in brachycephalic breeds, such as Bulldogs or Pugs, due to increased risk of respiratory obstruction from sedation-induced muscle relaxation. Regarding pregnancy, acepromazine is classified for cautious use only, as it may pose risks of teratogenicity or fetal harm, with benefits weighed against potential adverse outcomes by the veterinarian. Withdrawal from acepromazine does not typically cause significant clinical issues, but in food-producing animals, residues necessitate observation periods; while established withdrawal times exist in some regions (e.g., 7 days for meat in Canada), it is generally not recommended for animals intended for human consumption in the United States due to lack of approved withdrawal guidelines.

History and regulation

Development and approval

Acepromazine, a derivative of the class of compounds developed in the mid-20th century for applications, was synthesized as part of broader research into depressants during the early 1950s. This work built on the success of earlier phenothiazines like , aiming to create agents effective against psychotic disorders such as . Initial clinical trials in humans demonstrated some potential but were limited by significant adverse reactions, including severe and , leading to its rapid discontinuation for human use by the late 1950s. Following the abandonment of human applications due to safety concerns and limited efficacy, acepromazine transitioned to in the , where its properties proved valuable for animal handling and procedures. The U.S. (FDA) approved acepromazine maleate under New Animal Drug Application (NADA) #117-532 for use as a tranquilizer in , initially marketed as PromAce tablets. This approval marked a key milestone, enabling its widespread adoption for pre-anesthetic in veterinary practice, particularly for and horses. Early research in the focused on its in equine , with studies demonstrating reliable tranquilization at low doses, facilitating safer management during veterinary interventions. Subsequent milestones included the recognition in 2001 of heightened sensitivity to acepromazine in dogs carrying a mutation in the multidrug resistance 1 (MDR1) gene, particularly in herding breeds like Collies, prompting breed-specific dosage warnings to mitigate risks of neurotoxicity. Over time, veterinary research evolved from standalone use to emphasize combinations with other agents, such as opioids or alpha-2 agonists, for enhanced balanced anesthesia protocols, improving safety and efficacy in clinical settings.

Current status and availability

Acepromazine maleate is approved by the U.S. (FDA) for veterinary use as a tranquilizer in , , and , but it is not labeled for use in food-producing animals unless a suitable period is observed to prevent residues in meat or milk. In the , acepromazine is authorized under the trade name ACP for use in companion animals such as and , with formulations including tablets and injections available through veterinary prescription. In June 2025, acepromazine was included in the European Union's list of essential substances for the treatment of and other equines. It faces restrictions in equine , where it is classified as a banned substance with zero-tolerance policies in jurisdictions like those governed by the (FEI) and various national racing authorities, prohibiting its administration within specified withdrawal periods to ensure fair competition. Generic versions of acepromazine are widely available in the United States and internationally through veterinary pharmacies, often in tablet and injectable forms, while brand-name products include PromAce® for oral and injectable administration in , , and . Non-injectable formulations remain prescription-only in most regulated markets, with no verified over-the-counter availability for human or animal use. Reports of misuse have emerged, particularly in equine and animal shows, where acepromazine is sometimes administered illicitly to calm animals and mask stress or lameness, raising ethical concerns about and competition integrity. Ongoing veterinary research emphasizes safer alternatives, such as benzodiazepines like or combination protocols with and opioids, which provide effects with fewer cardiovascular risks compared to acepromazine alone. As of 2025, no significant regulatory changes have occurred regarding acepromazine's approval or availability, though there is increased emphasis in veterinary practice on routine MDR1 for breeds like Collies and Shepherds to identify dogs at risk of adverse reactions, enabling safer dosing or avoidance of the drug.

References

  1. [1]
    Acepromazine | C19H22N2OS | CID 6077 - PubChem - NIH
    Acepromazine is a member of the class of phenothiazines that is 10H-phenothiazine substituted by an acetyl group at position 2 and a 3-(dimethylamino)propyl ...
  2. [2]
  3. [3]
    [PDF] FOI Summary for the Original Approval of ANADA 200-757 August ...
    Aug 31, 2023 · Acepromazine Maleate Tablets are approved as an aid in tranquilization and as a preanesthetic agent in dogs. Acepromazine Maleate Tablets ...
  4. [4]
    Tranquilizers, Sedatives, and Analgesics for Treatment of Animals
    Sedation and ataxia are common adverse effects of acepromazine. Involuntary muscle movements, twitching, and dystonia can also occur.Acepromazine As A... · Alfaxalone As A Tranquilizer... · Propofol As A Tranquilizer...
  5. [5]
    [PDF] Acepromazine Maleate - U of A Open Textbooks
    Acepromazine inhibits central dopaminergic receptors to produce sedation and tranquilization.
  6. [6]
  7. [7]
    Phenothiazine - an overview | ScienceDirect Topics
    Unlike promazine, chlorpromazine and acepromazine both have an aliphatic side chain attached to the benzene ring structure at carbon position 2. The addition of ...Missing: relationship | Show results with:relationship
  8. [8]
    acepromazine maleate usp (30-3574) - PCCA
    DESCRIPTION, YELLOW CRYSTALLINE POWDER; ODORLESS OR ALMOST ODORLESS; PROTECT FROM LIGHT ; MELTING POINT, 136-139 °C ; PH, 4.0-5.5 ; SOLUBILITY, SOLUBLE IN WATER ...Missing: physical properties appearance pKa
  9. [9]
    ACEPROMAZINE MALEATE | 3598-37-6 - ChemicalBook
    solubility, H2O: >10mg/mL. pka, 9.3(at 25℃). form, powder. color, yellow. Water ... ACEPROMAZINE MALEATE Chemical Properties,Uses,Production. Description.Missing: appearance | Show results with:appearance
  10. [10]
    Acepromazine Maleate | C23H26N2O5S | CID 6420038 - PubChem
    Acepromazine Maleate is the maleate salt of acepromazine, a phenothiazine derivative with depressant effect on the central nervous system.Missing: appearance pKa
  11. [11]
  12. [12]
    Acepromazine for Dogs - PetMD
    Oct 11, 2024 · Acepromazine is a sedative and tranquilizer, often used as a preanesthetic in dogs, and to help with motion sickness. It slows the central ...Missing: pharmacology | Show results with:pharmacology
  13. [13]
    Acepromazine maleate Injection for Animal Use - Drugs.com
    Aug 27, 2025 · Acepromazine maleate injection, a potent neuroleptic agent with a low order of toxicity, is of particular value in the tranquilization of dogs, cats and horses.<|control11|><|separator|>
  14. [14]
    Acepromazine: Uses, Interactions, Mechanism of Action - DrugBank
    Aug 29, 2007 · Acepromazine is frequently used in animals as a sedative and antiemetic. Its principal value is in quietening and calming anxious animals.Identification · Pharmacology · Interactions · Categories
  15. [15]
    Acepromazine - an overview | ScienceDirect Topics
    Mechanism of action. The sedative and antiemetic ... Acepromazine maleate is the most commonly used phenothiazine tranquilizer in veterinary medicine.
  16. [16]
    Effects of acepromazine on the stress response in Southern chamois ...
    Acepromazine is a short-acting phenothiazine with central nervous system effects (blocking postsynaptic dopamine receptors), as well as anticholinergic, ...
  17. [17]
    Effect of acepromazine or dexmedetomidine associated with ...
    The reduction in arterial pressure resulting from acepromazine use is primarily mediated by α1-adrenergic receptor antagonism and is also dose-dependent ( ...
  18. [18]
    Acepromazine - an overview | ScienceDirect Topics
    Acepromazine is the most commonly used phenothiazine in veterinary medicine, primarily administered SC or IM to achieve good sedation before general anesthesia, ...
  19. [19]
    Effects of Maropitant Citrate or Acepromazine on the Incidence of ...
    ... chemoreceptor trigger zone (CRTZ).10. The purpose of this paper was to compare maropitant and acepromazine on the incidence of vomiting, signs of nausea ...Missing: mechanism | Show results with:mechanism
  20. [20]
    Acepromazine - an overview | ScienceDirect Topics
    Acepromazine is the most commonly used phenothiazine in veterinary medicine, primarily administered SC or IM to achieve good sedation before general anesthesia, ...
  21. [21]
    Acepromazine Injection(acepromazine maleate injection) - DailyMed
    Acepromazine [10-[3-(dimethyl-amino) propyl] phenothiazin-2-yl-methyl ketone] Maleate, USP has the following chemical structure: Picture of chemical structure ...
  22. [22]
    The Effect of Acepromazine Alone or in Combination with ...
    In ruminants, acepromazine causes sedation and mild skeletal muscle relaxation even in low doses; however, it does not possess antinociceptive properties [1].
  23. [23]
    Tramadol does not enhance sedation induced by acepromazine in ...
    The drug has been found to possess antagonistic action at dopaminergic receptors within the brain; this may explain the mechanism by which acepromazine induces ...
  24. [24]
    Feline procedural sedation and analgesia: When, why and how - PMC
    Acepromazine blocks dopaminergic receptors and decreases reaction to external stimuli. The drug has been used in combination with butorphanol, buprenorphine or ...
  25. [25]
    The Effect of the Canine ABCB1‐1Δ Mutation on Sedation after ...
    Jan 29, 2016 · ABCB1 mut/mut dogs have increased depth and duration of sedation after acepromazine IV compared to normal dogs (nor/nor).
  26. [26]
    P‐Glycoprotein Mediated Drug Interactions in Animals and Humans ...
    6 Acepromazine and butorphanol cause more profound and prolonged CNS depression in dogs with the MDR1 mutation compared to wild‐type dogs. Collectively, these ...
  27. [27]
    Acepromazine | VCA Animal Hospitals
    Are there any potential side effects? ... The most common and important side effect of acepromazine use is low blood pressure, and in severe cases, it can cause ...Missing: pharmacology | Show results with:pharmacology
  28. [28]
    Acepromazine Maleate for Dogs, Cats, and Horses
    Penile paralysis is a rare but recognized adverse side-effect of acepromazine use in the horse. This drug should be avoided in breeding stallions. Precautions.Basic Information · Horses · PrecautionsMissing: pharmacology | Show results with:pharmacology
  29. [29]
    Acepromazine maleate Injection - DailyMed
    Adverse reactions: A few rare but serious occurrences of idiosyncratic reactions to acepromazine may occur in dogs following oral or parenteral administration.
  30. [30]
    Hypotension in the horse induced by acepromazine maleate - PubMed
    The hypotensive effect of acepromazine maleate was related to both the dose and route of administration. The degree and duration of hypotension varied ...Missing: hypovolemic | Show results with:hypovolemic
  31. [31]
    Evaluation of acepromazine-induced hemodynamic alterations and ...
    Acepromazine diminishes monocyte TNF-α production, inhibits the differentiation of monocytes into macrophages (10,11), and decreases the production of reactive ...
  32. [32]
    [PDF] ANESTHESIA FOR THE EQUINE FOAL OR NEONATE
    Although there is evidence that foal kidneys are functionally mature at birth, liver metabolism is not generally mature until ~2 months and thus most drugs take.
  33. [33]
    Sedation and Anesthetic Management of Foals | Veterian Key
    Jul 8, 2016 · ... acepromazine) should be used cautiously unless they are reversible (opioids, benzodiazepines). In these young foals, the hepatic enzyme ...
  34. [34]
    Comparison of the sedative and cardiovascular effects of the ...
    Jan 15, 2024 · The aim of this study was to compare the sedative and cardiovascular effects of the combination of acepromazine-clonidine versus acepromazine-xylazine in ...Missing: cats | Show results with:cats
  35. [35]
    Sedatives and Tranquilizers | Veterian Key
    May 1, 2025 · Acepromazine has been among the most widely used sedatives in veterinary practice for many years and is labeled for use in small and large ...
  36. [36]
  37. [37]
    Acepromazine Dose For Dogs, Cats and Other Animal Species
    Dose of Acepromazine For Dogs, Cats & All Animals ; Cattle, 0.01–0.02, 0.03–0.1 ; Swine, —, 0.1–0.2 ; Ferret, —, 0.25–0.75 ; Rabbit, —, 0.75–1 ...
  38. [38]
    Drug prescription pattern in exotic pet and wildlife animal practice
    Jan 8, 2024 · This study aimed to describe the prescription patterns of drugs in exotic pets and wildlife animals attending the Veterinary Teaching Hospital of the ...<|control11|><|separator|>
  39. [39]
    Farm Animal Anesthesia | Veterian Key
    Sep 3, 2016 · The acepromazine dose for cattle is 0.03 to 0.05 mg/kg IV; for sheep ... The dose of acepromazine to tranquilize swine is 0.5 mg/kg IM.
  40. [40]
    Supplementary Table S2—Pork meat withdrawal ... - AVMA Journals
    Please note that withdrawal intervals may vary by country. Drug. Minimum Meat Withdrawal Interval. Acepromazine 7 days. Azaperone. 18 days. Butorphanol 4 days.Missing: cattle | Show results with:cattle
  41. [41]
    [PDF] RESTRAINT AND ANESTHESIA OF NATIVE WILDLIFE
    Adding 1 cc of acepromazine (10 mg) to a 10 cc bottle of ketamine (100 mg) creates a dissociative anesthetic with muscle relaxation properties. This combination ...
  42. [42]
    Immobilization of captive plains zebras (Equus quagga) with a ... - NIH
    We immobilized 30 captive plains zebra with a combination of etorphine hydrochloride (2–4 mg), acepromazine (8 mg), and xylazine hydrochloride (30 or 50 mg)
  43. [43]
    [PDF] use of immobilization and euthanasia drugs in wildlife damage ...
    Jun 6, 2023 · Nearly all immobilization drugs administered to wildlife require a veterinary prescription. ... Acepromazine maleate for veterinary use. in ...
  44. [44]
    Acute Acepromazine Overdose: Clinical Effects and Toxicokinetic ...
    Acepromazine overdose causes central nervous system and respiratory depression, hypotension, and rapid improvement within 8 hours, similar to other ...<|control11|><|separator|>
  45. [45]
    Using inotropes and vasopressors in anesthesia (Proceedings)
    If the primary cause of hypotension is peripheral vasodilation, e.g., acepromazine overdose, phenylephrine can be given immediately. If the patient is ...Missing: antidote | Show results with:antidote
  46. [46]
    Breed-Specific Anesthesia - WSAVA 2019 Congress - VIN
    Note that acepromazine has no analgesic properties and is not considered an adequate post-operative medication if a painful procedure has been performed. We ...Missing: pregnancy teratogenicity withdrawal
  47. [47]
    [PDF] annex i summary of product characteristics - Veterinary Medicines
    Using a dose of 0.15 mg / kg, the volume of distribution was 4.5 l / kg and the half-life was 1.6 h. The metabolism takes place mainly in the liver and ...<|separator|>
  48. [48]
    ACEPROMAZINE MALEATE tablet - DailyMed - NIH
    Approved by FDA under NADA # 117-532 - For use in dogs only. Approved by FDA under NADA # 117-532 ... acepromazine may occur in dogs following oral or ...
  49. [49]
    Pharmacologic treatment of priapism in two horses - AVMA Journals
    Penile erection in the horse after acepromazine. Vet Rec 1979;105:21-22. 7. Wheat JD. Penile paralysis in stallions given propio- promazine.
  50. [50]
    Treatment of MDR1 Mutant Dogs with Macrocyclic Lactones - PMC
    Accordingly, dogs with homozygous MDR1 mutation are in general prone to neurotoxicity by macrocyclic lactones due to their increased brain penetration.
  51. [51]
    Sedative effects of acepromazine in combination with nalbuphine or ...
    Oct 12, 2020 · The results of this study and previous studies reinforce that combinations of acepromazine with opioids cause low levels of sedation in cats ...Missing: evolution | Show results with:evolution
  52. [52]
    Bulk Drug Substances Currently Under Review - FDA
    Aug 19, 2025 · DOGS, CATS, HORSES ; Acepromazine maleate, dog, cat, horse, FDA-2018-N-4626-0114 ; Aluminum hydroxide, dog, cat, FDA-2018-N-4626-0048.
  53. [53]
    Implantation or Injectable Dosage Form New Animal Drugs
    Jun 17, 2004 · The ANADA provides for the veterinary prescription use of acepromazine maleate injectable solution in dogs, cats, and horses as a tranquilizer.
  54. [54]
    [PDF] 1. name of the veterinary medicinal product - HPRA
    Dec 6, 2024 · The maximum dose that should be given is 4 mg acepromazine per animal. Normally single doses of acepromazine are administered (see section ...
  55. [55]
    [PDF] Known Detection Times and Screening Limits of Common ... - HIWU
    • Banned Substance: prohibited at all times from being possessed ... Acepromazine. 1. 0.15 mg/kg single oral dose. 2. 0.05 mg/kg single IV dose. (20 ...Missing: zero tolerance
  56. [56]
    Development and validation of a quantitative UHPLC-HRMS ...
    May 22, 2025 · This study developed a UHPLC-HRMS method for quantifying banned substances in equine urine, including diazepam, acepromazine, ketoprofen, ...
  57. [57]
    [PDF] Doping in equine and its implications in race horses
    Aug 5, 2025 · follows a zero-tolerance policy, and offenders can face fines over £1,000, suspensions ranging from 2 to 10 years, and even disqualification.<|separator|>
  58. [58]
    ACEPROMAZINE Maleate (Generic) Tablets for Dogs, 25-mg - Chewy
    In stock Rating 4.7 (404) Acepromazine Maleate is a prescription medication for dogs who need tranquilization. This medication is not a pain reliever but can be used to sedate ...Missing: Acevet | Show results with:Acevet
  59. [59]
  60. [60]
    Acepromazine Maleate for Dogs - Valley Vet Supply
    In stock Rating 5.0 (13) Acepromazine Maleate for Dogs Generic (brand may vary) 13 Read Reviews | Write a review $59.99 - $87.99 Auto-Ship Icon Auto-Ship eligible Get 5% OFF with Auto- ...
  61. [61]
    Routine drugging of race horses 'disaster waiting to happen'
    Mar 30, 2025 · She said restricting the use of tranquillisers like acepromazine would cause mayhem in the industry because it had become too reliant on the use ...
  62. [62]
    Exploring the Confluence of Animal Medicine and its Implications for ...
    Originally approved for treating schizophrenia in humans, acepromazine is now exclusively licensed for veterinary use, although it is not classified as a ...
  63. [63]
    The medication violations in racehorses at Louisiana racetracks ...
    Jan 6, 2022 · All other drugs that are not regulated by ARCI with appropriate thresholds have zero tolerance rule (any level is considered violation). ...
  64. [64]
    Acepromazine - an overview | ScienceDirect Topics
    Acepromazine is defined as a phenothiazine derivative that acts as a central nervous system depressant, causing sedation through dopamine blockade while ...
  65. [65]
    Review of the Use of Pre-Visit Pharmaceuticals for Reducing Fear ...
    The use of acepromazine as a single agent is no longer recommended for the treatment of FAS, with studies showing no change in stress or anxiety scoring when ...
  66. [66]
    Gabapentin, melatonin, and acepromazine combination prior to ...
    Jul 26, 2023 · No pharmacokinetic or pharmacodynamic studies of OTM injectable acepromazine in dogs were found. However, IM acepromazine may take 30 to 40 ...
  67. [67]
    MDR1 in Dogs | Washington Animal Disease Diagnostic Laboratory
    At doses used to treat diarrhea, this drug will cause neurological toxicity in dogs with the MDR1 mutation. This drug should be avoided in all dogs with the ...
  68. [68]
  69. [69]
    Drug sensitivity: MDR1
    The most common signs of drug toxicity in dogs with MDR1 drug sensitivity include: Vomiting. Weakness. Uncoordinated movement. Tremors. Seizures. Blindness.